Dr. Cheng Cui, AstraZeneca

Dr. Cheng Cui is a regulatory affairs expert with over ten years’ experience across the FDA and industry, specializing in biomarkers, companion diagnostics and digital health. At the FDA, he was lead reviewer for digital and computational pathology devices. At AstraZeneca, he leads translational regulatory strategy for AI/ML-enabled computational pathology and developing biomarkers to advance precision medicine in oncology.